Structure-activity studies on lead cyclobutenedione 3 led to the discovery of 4 (SCH 527123), a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist with excellent cell-based activity. Compound 4 displayed good oral bioavailability in rat and may be a potential therapeutic agent for the treatment of various inflammatory diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm0609622 | DOI Listing |
Publication Analysis
Top Keywords
sch 527123
8
527123 potent
8
potent orally
8
orally bioavailable
8
bioavailable cxcr2/cxcr1
8
cxcr2/cxcr1 receptor
8
receptor antagonist
8
discovery 2-hydroxy-nn-dimethyl-3-{2-[[r-1-5-
4
2-hydroxy-nn-dimethyl-3-{2-[[r-1-5- methylfuran-2-ylpropyl]amino]-34-dioxocyclobut-1-enylamino}benzamide
4
methylfuran-2-ylpropyl]amino]-34-dioxocyclobut-1-enylamino}benzamide sch
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!